QHSLab (USAQ) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 15, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	0-19041
Entity Registrant Name	USA EQUITIES CORP.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, Address Line Three	West Palm
Entity Address, City or Town	Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Title of 12(b) Security	Common Stock, $0.0001 Par Value
Trading Symbol	USAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,756,093

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 543,311	$ 94,342
Accounts receivable	38,338	60,522
Inventory	101,236	99,701
Prepaid expenses and other current assets	37,321	11,598
Total current assets	720,206	266,163
Non-current assets:
Capitalized software development costs	139,865	31,700
Intangible assets, net	1,594,472
Total assets	2,454,543	297,863
Current Liabilities:
Accounts payable	87,560	145,422
Loans payable, current portion	776,911
Other current liabilities	14,857	14,198
Convertible note payable, related party		55,000
Total current liabilities	879,328	214,620
Non-current liabilities:
Accrued interest expenses	118,836	115,566
Convertible notes payable	407,377	576,003
Loans payable, non-current portion	464,456
Total long-term liabilities	990,669	691,569
Total liabilities	1,869,997	906,189
Stockholders’ Equity (Deficit):
Preferred stock, 10,000,000 shares authorized, $0.0001 par value; 1,080,092 shares issued and outstanding at September 30, 2021 and December 31, 2020	108	108
Common stock, 900,000,000 shares authorized, $0.0001 par value; 8,679,170 shares issued and outstanding at September 30, 2021 and 6,562,735 shares issued and outstanding at December 31, 2020	868	656
Additional paid-in capital	2,832,072	1,139,629
Accumulated deficit	(2,248,502)	(1,748,719)
Total stockholders’ equity (deficit)	584,546	(608,326)
Total liabilities and stockholders’ equity (deficit)	$ 2,454,543	$ 297,863

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	1,080,092	1,080,092
Preferred stock, shares outstanding	1,080,092	1,080,092
Common stock, shares authorized	900,000,000	900,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	8,679,170	6,562,735
Common stock, shares outstanding	8,679,170	6,562,735

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 324,479		$ 1,084,436
Cost of revenue	167,393		586,651
Gross profit	157,086		497,785
Operating Expenses:
Research and development	19,609	20,153	62,901	68,065
Sales and marketing	181,820	29,021	455,128	48,871
General and administrative	149,741	37,424	354,831	75,602
Loss on extinguishment of debt				21,299
Amortization	18,028		18,028
Total Operating Expenses	369,198	86,598	890,888	213,837
Net operating loss	(212,112)	(86,598)	(393,103)	(213,837)
Interest expense	88,658	6,850	106,680	19,880
Net loss	$ (300,770)	$ (93,448)	$ (499,783)	$ (233,717)
Basic and diluted net loss per share	$ (0.03)	$ (0.01)	$ (0.07)	$ (0.04)
Weighted average shares outstanding: (Basic and diluted)	8,646,399	6,388,822	7,570,228	6,078,611

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 576	$ 108	$ 990,856	$ (1,421,331)	$ (429,791)
Beginning balance, shares at Dec. 31, 2019	5,762,735	1,080,092
Stock-based compensation expense			155		155
Net loss				(78,419)	(78,419)
Ending balance, value at Mar. 31, 2020	$ 576	$ 108	991,011	(1,499,750)	(508,055)
Ending balance, shares at Mar. 31, 2020	5,762,735	1,080,092
Beginning balance, value at Dec. 31, 2019	$ 576	$ 108	990,856	(1,421,331)	(429,791)
Beginning balance, shares at Dec. 31, 2019	5,762,735	1,080,092
Net loss					(233,717)
Ending balance, value at Sep. 30, 2020	$ 656	$ 108	1,060,395	(1,655,048)	(593,889)
Ending balance, shares at Sep. 30, 2020	6,562,735	1,080,092
Beginning balance, value at Mar. 31, 2020	$ 576	$ 108	991,011	(1,499,750)	(508,055)
Beginning balance, shares at Mar. 31, 2020	5,762,735	1,080,092
Shares issued for services	$ 55		98,445		98,500
Shares issued for services, shares	550,000
Unearned compensation – shares issued for services			(72,281)		(72,281)
Stock-based compensation expense			1,085		1,085
Net loss				(61,850)	(61,850)
Ending balance, value at Jun. 30, 2020	$ 631	$ 108	1,018,260	(1,561,600)	(542,601)
Ending balance, shares at Jun. 30, 2020	6,312,735	1,080,092
Shares issued for services	$ 25		167,725		167,750
Shares issued for services, shares	250,000
Unearned compensation – shares issued for services			(128,511)		(128,511)
Stock-based compensation expense			2,921		2,921
Net loss				(93,448)	(93,448)
Ending balance, value at Sep. 30, 2020	$ 656	$ 108	1,060,395	(1,655,048)	(593,889)
Ending balance, shares at Sep. 30, 2020	6,562,735	1,080,092
Beginning balance, value at Dec. 31, 2020	$ 656	$ 108	1,139,629	(1,748,719)	(608,326)
Beginning balance, shares at Dec. 31, 2020	6,562,735	1,080,092
Shares issued for services	$ 15		89,985		90,000
Shares issued for services, shares	150,000
Unearned compensation – shares issued for services			(21,607)		(21,607)
Conversion of notes payable	$ 50		194,161		194,211
Conversion of notes payable, shares	496,718
Cancellation of shares	$ (10)		10
Cancellation of shares, shares	(100,000)
Cancellation of shares, shares	100,000
Stock-based compensation expense			8,920		8,920
Net loss				(86,686)	(86,686)
Ending balance, value at Mar. 31, 2021	$ 711	$ 108	1,411,098	(1,835,405)	(423,488)
Ending balance, shares at Mar. 31, 2021	7,109,453	1,080,092
Beginning balance, value at Dec. 31, 2020	$ 656	$ 108	1,139,629	(1,748,719)	(608,326)
Beginning balance, shares at Dec. 31, 2020	6,562,735	1,080,092
Net loss					(499,783)
Ending balance, value at Sep. 30, 2021	$ 868	$ 108	2,832,072	(2,248,502)	584,546
Ending balance, shares at Sep. 30, 2021	8,679,170	1,080,092
Beginning balance, value at Mar. 31, 2021	$ 711	$ 108	1,411,098	(1,835,405)	(423,488)
Beginning balance, shares at Mar. 31, 2021	7,109,453	1,080,092
Shares issued for services, net of cancellation	$ (7)		(41,893)		(41,900)
Shares issued for services, net of cancellation, shares	70,000
Shares issued for asset purchase	$ 125		862,375		862,500
Shares issued for asset purchase, shares	1,250,000
Share purchase	$ 5		29,995		30,000
Share purchase, shares	50,000
Unearned compensation – shares issued for services			99,344		99,344
Conversion of notes payable	26		132,049		132,075
Stock-based compensation expense			8,921		8,921
Net loss				(112,327)	(112,327)
Shares issued for services, net of cancellation, shares	(70,000)
Ending balance, value at Jun. 30, 2021	$ 860	$ 108	2,501,889	(1,947,732)	555,125
Ending balance, shares at Jun. 30, 2021	8,603,025	1,080,092
Shares issued for services	$ 4		33,196		33,200
Shares issued for services, shares	40,000
Shares issued in funding	$ 4		29,996		30,000
Shares issued in funding, shares	36,145
Warrants issued with convertible note payable			221,779		221,779
Unearned compensation – shares issued for services			36,291		36,291
Conversion of notes payable, shares	263,572
Stock-based compensation expense			8,921		8,921
Net loss				(300,770)	(300,770)
Ending balance, value at Sep. 30, 2021	$ 868	$ 108	$ 2,832,072	$ (2,248,502)	$ 584,546
Ending balance, shares at Sep. 30, 2021	8,679,170	1,080,092

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Operating activities
Net loss	$ (300,770)	$ (86,686)	$ (93,448)	$ (78,419)	$ (499,783)	$ (233,717)
Amortization	18,028				18,028		$ 0
Amortization of debt and warrant issuance costs					54,881
Stock-based compensation					26,762	4,161
Shares issued for services					195,328	65,458
Loss on extinguishment of debt						21,299
Changes in net assets and liabilities:
Decrease in accounts receivable					22,184
Increase in inventory					(1,535)
Increase in accrued interest					30,535	19,029
Increase in prepaid expenses and other current assets					(25,723)	(4,374)
(Decrease)/increase in accounts payable and accrued expenses					(56,808)	1,715
Cash flows from operating activities					(236,131)	(126,429)
Investing activities:
Capitalized software					(108,165)	(16,000)
Cash flows from investing activities					(108,165)	(16,000)
Financing activities:
Proceeds from sales of common stock					30,000
Issuance of convertible notes payable					850,000	55,000
Proceeds of loan borrowings					86,000
Repayments of loan borrowings					(87,735)
Payment of debt issuance costs					(85,000)
Proceeds of related-party borrowings						90,517
Cash flows from financing activities					793,265	145,517
Change in cash					448,969	3,088
Cash - beginning of year		$ 94,342		$ 23,590	94,342	23,590	23,590
Cash - end of period	$ 543,311		$ 26,678		543,311	26,678	$ 94,342
Supplemental noncash investing and financing activity:
Debt and accrued interest converted to shares of common stock					326,286
Debt and common stock issued for intangible assets (Note 4)					1,612,500
Common stock issued for debt issuance costs					30,000
Warrants issued in conjunction with convertible note payable					221,779
Conversion of due to related party to long-term debt						$ 88,016

The Company

The Company	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company USA Equities Corp. (the “Company”, “We” or the “Registrant”) was incorporated in Delaware on September 1, 1983. In 2015 the Company changed its name to USA Equities Corp. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada as a result of a merger with and into its newly formed wholly-owned subsidiary, USA Equities Corp., a Nevada corporation (“USA Equities Nevada”), the surviving entity pursuant to an Agreement and Plan of Merger. The reincorporation was approved by the stockholders of the Company and USA Equities Nevada is deemed to be the successor to USA Equities Corp, the Delaware corporation. On December 20, 2019 the Company entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (“MPI”) pursuant to a share exchange agreement (the “Exchange Agreement”) by which the Company issued 2,172,600 .0001 Prior to the transaction with MPI, the owner of a majority of the outstanding Class A voting shares of MPI owned approximately 91 % of our then outstanding shares. Consequently, the transaction with MPI was accounted for as a change in reporting entity between entities under common control, which requires retrospective combination of the entities for all periods as if the combination had been in effect since inception of common control in accordance with ASC 250-10-45-21, Accounting Changes and Error Corrections

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, has negative operating cash flows and began recognizing revenues in the fourth quarter of fiscal 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve profitability and positive cash flows and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Note 3. Basis of Presentation The condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes included in our Annual Report on Form 10- K for the year ended December 31, 2020. The accounting policies are described in the “Notes to the Consolidated Financial Statements” in the 2020 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three and nine months ended September 30, 2021 and 2020 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. Risks Related to COVID-19 Pandemic The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic could negatively impact the Company’s liquidity, capital resources and operations. The ultimate impact of the COVID-19 pandemic is highly uncertain and the Company does not yet know the full extent of potential impacts on its business, financing or global economy as a whole. Accounting Policies Use of Estimates Principles of Consolidation Cash and Cash Equivalents Accounts Receivable Inventories Capitalized Software Development Costs The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 139,865 31,700 no no Intangible Assets: Intangible assets represent the value the Company paid to acquire assets including a trademark, patent and web domain on June 23, 2021. The provisional allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. These assets are accounted for in accordance with ASC 350-30, Intangibles, General Intangibles Other Than Goodwill. The cost of the assets is amortized over the remaining useful life of the assets as follows: Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. Research and Development : Research and development expense is primarily related to developing and improving methods related to the Company’s Software as a Service (SaaS) platform. Research and development expenses are expensed when incurred. For the nine months ended 30, 2021 and 2020, there was $ 62,901 and $ 68,065 , respectively, of research and development expenses incurred. Earnings Per Common Share no Income Taxes Income Taxes, The Company has net operating losses of $ 2,217,514 begin to expire in 2027 Recently Issued Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Capitalized Software and Intang

Capitalized Software and Intangible Assets	9 Months Ended
	Sep. 30, 2021
Research and Development [Abstract]
Capitalized Software and Intangible Assets	Note 4. Capitalized Software and Intangible Assets Non-current assets consist of the following at September 30, 2021 and December 31, 2020: Schedule of Intangible Assets Estimated Useful Life (in years) September 30, 2021 December 31, 2020 Capitalized Software TBD $ 139,865 $ 31,700 Intangible Assets: U.S. Method Patent 13.4 967,500 - Web Domain N/A 161,250 - Trademark N/A 483,750 - Total Intangible Assets $ 1,612,500 $ - Accumulated amortization (18,028 ) - Intangible assets, net $ 1,594,472 $ - Capitalized software represents the development costs for internal-use software. The software application is still in development with costs continuing to be capitalized and no amortization expense being recognized yet. Capitalization will cease and amortization will begin once development is substantially complete. The Capitalized software costs will be amortized over the estimated life of the software. There were no impairments recognized during the periods ended September 30, 2021 and December 31, 2020. The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021. The provisional allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. Intangibles, General Intangibles Other Than Goodwill 18,028 of amortization expense during the three month period ended September 30, 2021 and no amortization expense during the period ended December 31, 2020.

Loans Payable

Loans Payable	9 Months Ended
	Sep. 30, 2021
Loans Payable
Loans Payable	Note 5. Loans Payable On June 21, 2021, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 86,000 in loan proceeds. The loan payable, which is classified within current liabilities, will be repaid in nine months of the original loan date with the merchant bank withholding an agreed-upon percentage of payments they process on behalf of the Company. As of September 30, 2021, the loan balance is $ 52,566 . On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (“MedScience”) (See Note 4 for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $ 750,000 36 695,699

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 6. Convertible Notes Payable Convertible notes payable at September 30, 2021 and December 31, 2020 consist of the following: Schedule of Convertible Notes Payable September 30, 2021 December 31, 2020 Note 1 and accrued interest and premium – Principal shareholder $ 201,774 $ 195,177 Note 2 and accrued interest – Principal shareholder 127,142 126,210 Note 3 and accrued interest – Shareholder - 62,951 Note 4 and accrued interest – Principal shareholder - 97,537 Note 5 and accrued interest – Accredited investors - 56,462 Note 6 and accrued interest – Principal shareholder 93,297 89,347 Note 7 and accrued interest – Accredited investors - 101,781 Note 8 and accrued interest – Accredited investors 26,925 25,055 Note 9 and accrued interest – Shareholder 104,000 - Note 10 and accrued interest, net of discount and issuance costs – Mercer Note 473,733 - Total Convertible notes payable and accrued interest $ 1,026,871 $ 754,520 Note 1 – In October 2009, the Company issued a Convertible Promissory Note with a principal amount of $ 73,500 12 June 30, 2023 0.10 Debt, Modification and Extinguishments 21,299 106,975 100,378 Note 2 – Effective September 1, 2019, the Company issued a Convertible Promissory Note in the principal amount of $ 124,562 1 December 30, 2022 0.25 2,580 1,648 Note 3 – Effective September 12, 2019, the Company issued a Convertible Promissory Note in the principal amount of $ 55,000 12 0.25 55,000 7,951 0.25 251,805 Note 4 – Effective December 27, 2019, the Company issued a Convertible Promissory Note in the principal amount of $ 88,626 10 December 30, 2022 0.55 88,626 11,096 0.55 181,313 0 8,911 Note 5 – Under subscription agreements dated September 25, 2020, the Company issued Convertible Promissory Notes (the “Notes”) to various individuals totaling $ 55,000 10 September 30, 2022 The Company could satisfy the Notes upon maturity or Default, as defined, by the issuance of Common shares at a conversion price equal to the greater of a 20% discount to the 15 day average market price of the Company’s common stock or $0.10. The principal and interest accrued are convertible at any time after six months through the Maturity Date at the option of the holder at a 20% discount to the 15 day average market price of the Company’s share price, but in no event less than $0.10 per share. Upon conversion of any portion of the Notes, the investor will receive warrants to purchase up to 25% of the number of common shares issued as a result of such conversion exercisable for a period of two years at a price per share equal to 150% of the conversion price of the Notes. As of March 31, 2021 one of the note holders had elected to convert outstanding principal of $ 30,000 63,600 0.50 15,900 0.75 As of June 17, 2021 the other note holder had elected to convert outstanding principal of $ 25,000 48,755 0.55 12,189 0.83 As of September 30, 2021 and December 31, 2020, these notes had accumulated $ 0 1,462 Note 6 – Effective September 30, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 88,016 6 December 31, 2022 1.00 5,281 1,331 Note 7 – Effective October 27, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 September 25, 2020 100,000 214,817 0.49 53,704 0.74 0 1,781 Note 8 – Effective December 23, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 25,000 September 25, 2020 1,925 55 Note 9 – Effective May 7, 2021, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 10% September 30, 2022 The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of Common shares at a conversion price equal to the greater of a 25% discount to the 15 day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time after six months through the maturity date of September 30, 2022 at the option of the holder at a 25% discount to the 15 day average market price of the Company’s share price, but in no event less than $0.50 per share. 4,000 Note 10 – Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the “Note”) in the principal amount of $ 806,000 930,000 750,000 The principal amount of the Note and all interest accrued thereon is payable on August 10, 2022, and are secured by a lien on substantially all of the Company’s assets. The Note provides for interest at the rate of 5 % per annum, payable at maturity, and is convertible into common stock at a price of $ 0.65 per share. In addition to customary anti-dilution adjustments upon the occurrence of certain corporate events, the Note provides, subject to certain limited exceptions, that if we issue any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such stock or common stock equivalents were sold. The conversion price of the Note had been subject to a potential decrease if the average closing price of the Company’s common stock during any ten consecutive trading days beginning September 16, 2021, and ending on November 15, 2021, was below $ 0.65 0.65 The 930,000 1.25 The Company accounts for the allocation of its issuance costs to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options. Under this guidance, if debt or stock is issued with detachable warrants, the proceeds need to be allocated to the two instruments using either the fair value method, the relative fair value method, or the residual value method. The Company used the relative fair value at the time of issuance to allocate the value received between the convertible note and the warrants. The Company estimated the fair value of warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital. The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which are being recognized over the life of the note, along with associated interest, is recorded with current liabilities on the Company’s Condensed Consolidated Balance Sheet. As of September 30, 2021, this note had accumulated $ 5,631 of accrued interest, total unamortized debt issuance costs of $ 289,723 48,175

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Preferred Stock	Note 7. Preferred Stock Issuance of Series A Preferred Stock Effective September 1, 2019, the Company issued 1,080,092 shares of Series A Preferred Stock in satisfaction of a previously issued convertible promissory note held by its principal shareholder in the initial principal amount of $ 255,681 together with all interest accrued thereon. The shares of Series A Preferred Stock have a stated value of $ 0.25 0.05 The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote.

Loss Per Common Share

Loss Per Common Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Loss Per Common Share	Note 8. Loss Per Common Share The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the nine months ended September 30, 2021 and 2020 as the result would be anti-dilutive. Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share Nine Months Ended September 30, 2021 2020 Stock options 1,100,000 650,000 Stock warrants 1,019,793 - Total shares excluded from calculation 2,119,793 650,000

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Note 9. Stock-based Compensation During the nine months ended September 30, 2021 and 2020, there was $ 26,762 4,161 195,328 65,458 Schedule of Stock-based Compensation Expenses Nine Months Ended September 30, 2021 2020 Research and development $ 29,031 $ 35,844 Sales and marketing 98,332 22,531 General and administrative 67,965 7,083 Total expense – shares issued for services $ 195,328 $ 65,458 During the nine months ended September 30, 2021, there were 450,000 0.65 three years five years During the nine months ended 30, 2020, there were 650,000 0.40 three years five years As of September 30, 2021, there was $ 45,006 1,100,000 16 0.12 The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Nine Months Ended Nine Months Ended Risk-free interest rate 0.21 % 0.51 % Expected life of the options 3.5 3.5 Expected volatility of the underlying stock 76.3 % 70.7 % Expected dividend rate 0 % 0 % The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. The expected life of the options is based on the option term. Due to the Company’s limited historical data, the expected volatility is calculated based upon the historical volatility of comparable companies whose share prices are publicly available for a sufficient period of time. The dividend rate is based on the Company never paying or having the intent to pay any cash dividends. On March 8, 2021, the Company entered into a Consulting Agreement (“Agreement 1”) with an Investor Relations Consultant, pursuant to which the Investor Relations Consultant was to provide investor relations services to the Company for consideration of 120,000 On March 10, 2021, the Company entered into a Consulting Agreement (“Agreement 2”) with a Legal Consultant to provide legal services to the Company for consideration of 30,000 16 On May 5, 2021, the Company entered into a Consulting Agreement (“Agreement 3”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 30,000 shares of common stock of the Company (the “Share Payment”). The term of Agreement 3 was three months and the value of the shares was expensed over the term. On June 14, 2021, the Company entered into a one-month Consulting Agreement (“Agreement 4”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 20,000 shares of common stock of the Company (the “Share Payment”). On July 16, 2021, the Company entered into a one-month Consulting Agreement (“Agreement 5”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 20,000 shares of common stock of the Company (the “Share Payment”). On August 16, 2021, the Company entered into a one-month Consulting Agreement (“Agreement 6”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 20,000 shares of common stock of the Company (the “Share Payment”). Options outstanding at September 30, 2021 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 12, 2020 500,000 333,333 $ 0.40 December 31, 2024 June 27, 2020 150,000 100,000 $ 0.40 December 31, 2024 January 1, 2021 450,000 150,000 $ 0.65 December 31, 2025 Total 1,100,000 583,667 Warrants outstanding at September 30, 2021 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 Total 1,019,793 1,019,793

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	Note 10. Related-Party Transactions Convertible notes payable, related party:

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11. Commitments and Contingencies On February 9, 2021, the Company entered into a Receivables Purchase and Security Agreement (“Factoring Agreement”) with a Factoring Company. The Factoring Agreement has an initial term of one year Under the terms of the agreement, designated receivables are sold for periodic advances of up to $ 150,000 10 1.8 Amounts due from the Factoring Company, net of fees, are typically included in Prepaid expenses and other current assets on the Condensed Consolidated Balance Sheet. As of September 30, 2021, the balance due to the Factoring Company is included with other current liabilities on the Condensed Consolidated Balance Sheet. There are no pending or threatened legal proceedings as of September 30, 2021. The Company has no non-cancellable operating leases.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable
Inventories	Inventories
Capitalized Software Development Costs	Capitalized Software Development Costs The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 139,865 31,700 no no Intangible Assets: Intangible assets represent the value the Company paid to acquire assets including a trademark, patent and web domain on June 23, 2021. The provisional allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. These assets are accounted for in accordance with ASC 350-30, Intangibles, General Intangibles Other Than Goodwill. The cost of the assets is amortized over the remaining useful life of the assets as follows: Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life
Revenue Recognition	Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.
Research and Development	Research and Development : Research and development expense is primarily related to developing and improving methods related to the Company’s Software as a Service (SaaS) platform. Research and development expenses are expensed when incurred. For the nine months ended 30, 2021 and 2020, there was $ 62,901 and $ 68,065 , respectively, of research and development expenses incurred.
Earnings Per Common Share	Earnings Per Common Share no
Income Taxes	Income Taxes Income Taxes, The Company has net operating losses of $ 2,217,514 begin to expire in 2027
Recently Issued Accounting Standards	Recently Issued Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life

Capitalized Software and Inta_2

Capitalized Software and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Research and Development [Abstract]
Schedule of Intangible Assets	Non-current assets consist of the following at September 30, 2021 and December 31, 2020: Schedule of Intangible Assets Estimated Useful Life (in years) September 30, 2021 December 31, 2020 Capitalized Software TBD $ 139,865 $ 31,700 Intangible Assets: U.S. Method Patent 13.4 967,500 - Web Domain N/A 161,250 - Trademark N/A 483,750 - Total Intangible Assets $ 1,612,500 $ - Accumulated amortization (18,028 ) - Intangible assets, net $ 1,594,472 $ -

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable at September 30, 2021 and December 31, 2020 consist of the following: Schedule of Convertible Notes Payable September 30, 2021 December 31, 2020 Note 1 and accrued interest and premium – Principal shareholder $ 201,774 $ 195,177 Note 2 and accrued interest – Principal shareholder 127,142 126,210 Note 3 and accrued interest – Shareholder - 62,951 Note 4 and accrued interest – Principal shareholder - 97,537 Note 5 and accrued interest – Accredited investors - 56,462 Note 6 and accrued interest – Principal shareholder 93,297 89,347 Note 7 and accrued interest – Accredited investors - 101,781 Note 8 and accrued interest – Accredited investors 26,925 25,055 Note 9 and accrued interest – Shareholder 104,000 - Note 10 and accrued interest, net of discount and issuance costs – Mercer Note 473,733 - Total Convertible notes payable and accrued interest $ 1,026,871 $ 754,520

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share	The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the nine months ended September 30, 2021 and 2020 as the result would be anti-dilutive. Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share Nine Months Ended September 30, 2021 2020 Stock options 1,100,000 650,000 Stock warrants 1,019,793 - Total shares excluded from calculation 2,119,793 650,000

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expenses	Schedule of Stock-based Compensation Expenses Nine Months Ended September 30, 2021 2020 Research and development $ 29,031 $ 35,844 Sales and marketing 98,332 22,531 General and administrative 67,965 7,083 Total expense – shares issued for services $ 195,328 $ 65,458
Schedule of Fair Value of Option Grant of Weighted-average Assumptions	The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Nine Months Ended Nine Months Ended Risk-free interest rate 0.21 % 0.51 % Expected life of the options 3.5 3.5 Expected volatility of the underlying stock 76.3 % 70.7 % Expected dividend rate 0 % 0 %
Schedule of Options Outstanding and Exercisable	Options outstanding at September 30, 2021 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 12, 2020 500,000 333,333 $ 0.40 December 31, 2024 June 27, 2020 150,000 100,000 $ 0.40 December 31, 2024 January 1, 2021 450,000 150,000 $ 0.65 December 31, 2025 Total 1,100,000 583,667
Schedule of Warrants Outstanding and Exercisable	Warrants outstanding at September 30, 2021 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 Total 1,019,793 1,019,793

The Company (Details Narrative)

The Company (Details Narrative) - $ / shares	Dec. 20, 2019	Sep. 30, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001
Medical Practice Income, Inc. [Member] | Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued during period, for share exchange	2,172,600
Common stock, par value	$ 0.0001
Equity Method Investment, Ownership Percentage	91.00%

Schedule of Indefinite-Lived In

Schedule of Indefinite-Lived Intangible Assets (Details)	9 Months Ended
	Sep. 30, 2021
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired Intangible Asset	Indefinite life
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired Intangible Asset	Indefinite life
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Capitalized software development costs	$ 139,865		$ 139,865		$ 31,700
Amortization expenses of capitalized software development			0		0
Capitalized software development cost impairments recognized			0		$ 0
Research and Development Expense	19,609	$ 20,153	$ 62,901	$ 68,065
Common stock equivalent shares of weighted average shares outstanding dilutive			2,119,793	650,000
Net operating losses	$ 2,217,514		$ 2,217,514
Net operating losses carryforwards, expire date			begin to expire in 2027
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalent shares of weighted average shares outstanding dilutive			0	0

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 1,612,500
Accumulated amortization	(18,028)
Intangible assets, net	1,594,472
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	139,865	31,700
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 967,500
Finite-lived intangible assets, amortization method	13 years 4 months 24 days
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 161,250
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 483,750

Capitalized Software and Inta_3

Capitalized Software and Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Research and Development [Abstract]
Capitalized Computer Software, Impairments			$ 0		$ 0
Depreciation, Depletion and Amortization	$ 18,028		$ 18,028		$ 0

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Jun. 23, 2021	Jun. 30, 2021	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Issuance of Debt		$ 86,000
Loans Payable			$ 52,566
Debt principal amount and accrued interest			$ 695,699
Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Principal amount	$ 750,000
Debt periodic payment	$ 36

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	$ 1,026,871	$ 754,520
Convertible Notes Payable One [Member] | Majority Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	201,774	195,177
Convertible Notes Payable Two [Member] | Majority Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	127,142	126,210
Convertible Notes Payable Three [Member] | Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		62,951
Convertible Notes Payable Four [Member] | Majority Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		97,537
Convertible Notes Payable Five [Member] | Investor [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		56,462
Convertible Notes Payable Six [Member] | Majority Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	93,297	89,347
Convertible Notes Payable Seven [Member] | Investor [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		101,781
Convertible Notes Payable Eight [Member] | Investor [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	26,925	25,055
Convertible Notes Payable Nine [Member] | Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	104,000
Convertible Notes Payable Ten [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	$ 473,733

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)

Aug. 10, 2021

May 07, 2021

Mar. 31, 2021

Jan. 02, 2021

Dec. 23, 2020

Oct. 27, 2020

Sep. 30, 2020

Sep. 25, 2020

Feb. 27, 2020

Dec. 27, 2019

Sep. 01, 2019

Sep. 30, 2020

Nov. 15, 2021

Sep. 30, 2021

Sep. 21, 2021

Jun. 17, 2021

Dec. 31, 2020

Sep. 12, 2019

Oct. 31, 2009

Short-term Debt [Line Items]

Unamortized debt issuance costs

$ 289,723

Debt discount

48,175

Convertible Notes Payable Nine [Member] | Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, maturity date

Sep. 30, 2022

Accrued interest

4,000

Convertible Notes Payable Ten [Member] | Mercer Street Global Opportunity Fund LLC [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 806,000

Warrants issued to purchase of common stock.

930,000

Proceeds from warrant in consideration

$ 750,000

Convertible Promissory Note Ten [Member] | Accredited Investors [Member]

Short-term Debt [Line Items]

Accrued interest

5,631

Majority Shareholder [Member] | Convertible Promissory Note Ten [Member]

Short-term Debt [Line Items]

Debt instrument, interest rate

5.00%

Debt instrument, conversion price

$ 0.65

$ 0.65

Warrants exercise price

$ 1.25

Warrants exercised

930,000

Majority Shareholder [Member] | Convertible Promissory Note Ten [Member] | Subsequent Event [Member]

Short-term Debt [Line Items]

Debt instrument, conversion price

$ 0.65

Other Majority Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 25,000

Debt instrument, conversion price

$ 0.55

Accrued interest

$ 48,755

Warrants exercise price

$ 0.83

Warrants to purchase common stock

12,189

Convertible Notes Payable One [Member]

Short-term Debt [Line Items]

Debt instrument, maturity date

Jun. 30, 2023

Convertible Notes Payable One [Member] | Majority Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 73,500

Debt instrument, interest rate

12.00%

Debt instrument, conversion price

$ 0.10

Extinguishment of debt

$ 21,299

Accrued interest

106,975

$ 100,378

Convertible Notes Payable Two [Member] | Majority Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 124,562

Debt instrument, interest rate

1.00%

Debt instrument, maturity date

Dec. 30, 2022

Debt instrument, conversion price

$ 0.25

Accrued interest

2,580

1,648

Convertible Notes Payable Three [Member] | Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 55,000

$ 55,000

Debt instrument, interest rate

12.00%

Debt instrument, conversion price

$ 0.25

Accrued interest

$ 7,951

Common stock at a price

$ 0.25

Issuance of shares common stock

251,805

Convertible Notes Payable Four [Member] | Majority Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 88,626

$ 88,626

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Dec. 30, 2022

Debt instrument, conversion price

$ 0.55

Accrued interest

$ 11,096

0

8,911

Common stock at a price

$ 0.55

Issuance of shares common stock

181,313

Convertible Notes Payable Five [Member] | Investor [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 30,000

$ 55,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Sep. 30, 2022

Debt instrument, conversion price

$ 0.50

Accrued interest

0

1,462

Issuance of shares common stock

63,600

Debt Instrument, Description

The Company could satisfy the Notes upon maturity or Default, as defined, by the issuance of Common shares at a conversion price equal to the greater of a 20% discount to the 15 day average market price of the Company’s common stock or $0.10. The principal and interest accrued are convertible at any time after six months through the Maturity Date at the option of the holder at a 20% discount to the 15 day average market price of the Company’s share price, but in no event less than $0.10 per share. Upon conversion of any portion of the Notes, the investor will receive warrants to purchase up to 25% of the number of common shares issued as a result of such conversion exercisable for a period of two years at a price per share equal to 150% of the conversion price of the Notes.

Convertible Notes Payable Five [Member] | Investor [Member] | Warrant [Member]

Short-term Debt [Line Items]

Issuance of shares common stock

15,900

Warrants exercise price

$ 0.75

Convertible Notes Payable Six [Member] | Majority Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 88,016

$ 88,016

Debt instrument, interest rate

6.00%

6.00%

Debt instrument, maturity date

Dec. 31, 2022

Debt instrument, conversion price

$ 1

$ 1

Accrued interest

5,281

1,331

Convertible Notes Payable Seven [Member] | Investor [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 100,000

$ 100,000

Debt instrument, maturity date

Sep. 25, 2020

Debt instrument, conversion price

$ 0.49

Accrued interest

$ 214,817

0

1,781

Warrants exercise price

$ 0.74

Warrants to purchase common stock

53,704

Convertible Notes Payable Eight [Member] | Investor [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 25,000

Debt instrument, maturity date

Sep. 25, 2020

Accrued interest

$ 1,925

$ 55

Convertible Notes Payable Nine [Member] | Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 100,000

Debt instrument, interest rate

10.00%

10.00%

Debt Instrument, Description

The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of Common shares at a conversion price equal to the greater of a 25% discount to the 15 day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time after six months through the maturity date of September 30, 2022 at the option of the holder at a 25% discount to the 15 day average market price of the Company’s share price, but in no event less than $0.50 per share.

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Sep. 01, 2019	Sep. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Preferred stock stated value		$ 0.0001	$ 0.0001
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	1,080,092
Debt Instrument, Face Amount	$ 255,681
Preferred stock stated value		0.25
Debt instrument, conversion price		$ 0.05
Preferred stock voting rights description		The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote.

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	2,119,793	650,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,100,000	650,000
Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,019,793

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expenses (Details) - Shares Issued For Services [Member] - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	$ 195,328	$ 65,458
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	29,031	35,844
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	98,332	22,531
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	$ 67,965	$ 7,083

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Grant of Weighted-average Assumptions (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.21%	0.51%
Expected life of the options	3 years 6 months	3 years 6 months
Expected volatility of the underlying stock	76.30%	70.70%
Expected dividend rate	0.00%	0.00%

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Mar. 12, 2020
Number Outstanding	500,000
Number Exercisable	333,333
Exercise Price | $ / shares	$ 0.40
Expiration Date	Dec. 31, 2024
Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Jun. 27, 2020
Number Outstanding	150,000
Number Exercisable	100,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Dec. 31, 2024
Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Jan. 1, 2021
Number Outstanding	450,000
Number Exercisable	150,000
Exercise Price | $ / shares	$ 0.65
Expiration Date	Dec. 31, 2025
Options Held [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding	1,100,000
Number Exercisable	583,667

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Mar. 16, 2021
Number Outstanding	15,900
Number Exercisable	15,900
Exercise Price | $ / shares	$ 0.75
Expiration Date	Mar. 15, 2023
Warrant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	May 7, 2021
Number Outstanding	53,704
Number Exercisable	53,704
Exercise Price | $ / shares	$ 0.74
Expiration Date	May 6, 2023
Warrant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Jun. 17, 2021
Number Outstanding	12,189
Number Exercisable	12,189
Exercise Price | $ / shares	$ 0.83
Expiration Date	Jun. 16, 2023
Warrant Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Aug. 10, 2021
Number Outstanding	930,000
Number Exercisable	930,000
Exercise Price | $ / shares	$ 1.25
Expiration Date	Aug. 9, 2024
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding	1,019,793
Number Exercisable	1,019,793

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative)	Jun. 14, 2021shares	May 05, 2021shares	Mar. 10, 2021shares	Mar. 08, 2021shares	Aug. 16, 2021shares	Jul. 16, 2021shares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation | $							$ 26,762	$ 4,161
Unrecognized compensation related to unvested options | $							$ 45,006
Unrecognized compensation related to unvested options, shares							1,100,000
Recognized weighted-average period							16 months
Weighted-average fair value for options granted							0.0012
Consulting Agreement One [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued in consideration				120,000
Consulting Agreement Two [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued in consideration			30,000
Agreement term period			16 months
Consulting Agreement Three [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued in consideration		30,000
Agreement term period		3 months
Consulting Agreement Four [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued in consideration	20,000
Consulting Agreement Five [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued in consideration						20,000
Consulting Agreement Six [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued in consideration					20,000
Scientific Advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted							450,000	650,000
Weighted-average exercise price | $ / shares							$ 0.65	$ 0.40
Options vesting term							3 years	3 years
Options expiration period							5 years	5 years
Shares Issued For Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services | $							$ 195,328	$ 65,458

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Factoring Agreement [Member]	Feb. 09, 2021USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement term	1 year
Advances on sale on receivables	$ 150,000
Reserve of purchased receivables, percentage	10.00%
Factoring fees, percentage	1.80%